You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Rapid Point-of-Care Diagnostics to Detect Serologic Status of Individuals for Select Viral Infections

    SBC: Zymeron Corporation            Topic: NIAID

    CytomegalovirusCMVis a very common intrauterine infectionaffecting approximately one in everychildrenThe overall disease burden in the US with congenital CMV was estimated at $billion annuallyCMV is also a cause of serious morbidity and fatal infections in immunocompromised patientsThere is currently no generally accepted therapy and developing a CMV vaccine is high priorityCurrently CMV trials re ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  2. TOPIC #366- PHASE II SBIR CONTRACT- CLONOGENIC HIGH- THROUGHPUT ASSAY FOR SCREENING RADIATION MODULATION

    SBC: SuviCa, Inc.            Topic: NCI

    Clonogenic assays measure the ability of single cells to proliferate and form a colonyThis process approximates closely the regrowth and recurrence of tumors after treatment with radiation or chemotherapyproviding an assay to screen for drugs that block this processYetclonogenic assays are labor intensive and too cumbersome for high throughout screeningHTSof compound librariesHere we propose to de ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Improving spatiotemporal precision in noninvasive electrical neuromodulation

    SBC: Brain Electrophysiology Laboratory Company, LLC            Topic: 101

    This application describes the commercialization of the Geodesic Transcranial Electrical Neuromodulation (GTEN) technology to achieve noninvasive neuromodulation with improved spatiotemporal precision. The GTEN system enables both EEG source analysis and configurable electrical neuromodulation with the 256 electrodes of the Geodesic Sensor Net. Now in beta release to selected research customers, t ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Whole-organ bioreactor with integrated nondestructive 3D molecular imaging

    SBC: Sonovol, Inc.            Topic: NHLBI

    Abstract Significance: Donor tissue shortage remains a critical problem in lung transplantation. Recent advances in tissue engineering have allowed for the possibility of generating bioengineered lungs from decellularized organ scaffolds. These scaffolds, created from the donor’s tissue, become functionalized after recellularization with a patient’s own cells. However, translation of whole-lun ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Personal Mercury Monitor for Exposure Measurements

    SBC: First American Scientific Corporati            Topic: 113

    Personal Mercury Monitor for Exposure Measurements Project Summary/AbstractWorkers in the oil and natural gas industry are vulnerable to exposure to toxic mercury (Hg) vapor as a result of routine inspection and maintenance of equipment such as compressors and other process equipment that concentrate species of low volatility over time. Exposure of workers to elemental mercury vapor is of concern ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  6. High Throughput CRISPR/Cas9 cell line generation using the CellRaft Array

    SBC: Cell Microsystems, Inc.            Topic: 400

    Project SummaryGenome editing technologies, such as CRISPR/Cas9 provide a rapid, and targeted means of both knocking out gene expression and knocking in gene modifications. Since our initial Phase I submission, the utility of CRISPR technology has expanded beyond the generation of cell lines, to forward genetic screening, in vivo manipulation of gene expression and even human therapeutics. Phase I ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Point-of-Care Prognostic Tool for Sepsis

    SBC: Mbio Diagnostics, Inc.            Topic: 300

    Sepsis is a devastating cause of morbidity and mortality in intensive care units (ICUs), with estimates of U.S. incidence ranging from 894,000 to 3.1 million cases annually. The heterogeneity of clinical presentation (etiology, patient history, severity, etc.) creates a major challenge for patient management and has significantly complicated development of new therapies, almost all of which have f ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Development of Novel Compounds for Treatment of Heart Arrhythmias in CPVT

    SBC: Elex Biotech, Inc            Topic: NHLBI

    PROJECT SUMMARY The goal of this project is to complete the preclinical development of Elex Biotechandapos;s novel compounds that target and treat the underlying molecular cause of catecholaminergic polymorphic ventricular tachycardia (CPVT) CPVT. There are no FDA-approved treatments for CPVT, a rare genetic disorder affecting 1/10,000 individuals, with typical onset in children 7-9 years of age a ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Software for predicting a drug's potential to cause acute kidney injury

    SBC: DILIsym Services, Inc.            Topic: 400

    The goal of this project is to develop novel technology for predicting drug-induced kidney injury such as caused by systemic antimicrobials, diuretics, anticancer agents, and anti-inflammatory drugs. Drugs cause approximately 20 percent of community- and hospital- acquired episodes of acute renal failure, but the incidence in older adults may be as high as 60 percent. A significant problem is that ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  10. A Single-Cell Proteomic instrument for Predictive Product Quality Check in Autologous CAR-T Immunotherapies

    SBC: IsoPlexis            Topic: 102

    While CAR-T therapies have advanced in the clinic, there are still two specific issues using these breakthrough therapies for blood cancers: Durable responses in patients are only at 30-50% and Cytokine Release Syndrome occurs in 60-90% of treated patients. These limitations, for a drug that costs as much as $500,000, may cost an additional $250,000+ for treating adverse events leading to caution ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government